PuraPharm

What PuraPharm does

PuraPharm is a Hong Kong-headquartered Traditional Chinese Medicine (TCM) company operating as the No. 1 market leader in Concentrated Chinese Medicine Granules (CCMG) in Hong Kong with approximately 70% domestic market share. Founded in 1998 and listed on the Hong Kong Stock Exchange (hkg:1498), PuraPharm develops, manufactures, and distributes standardized CCMG formulations alongside a broader consumer health portfolio spanning Lingzhi, Haveron, CardioClear, and Oncozac branded products. The company holds the exclusive position as the only non-PRC enterprise licensed by China's NMPA to manufacture and sell CCMG within mainland China, and its manufacturing operations are USP-verified, GMP-certified, and backed by a CNAS-accredited laboratory and 24 international quality accreditations.

The company operates a vertically integrated, multi-channel business model. Its B2B core sells standardized CCMG formulations to TCM practitioners for clinical dispensing, embedding PuraPharm into practitioner workflows. A consumer products division addresses OTC and wellness demand through retail and pharmacy distribution. A chain of Nong's Chinese Medicine clinics provides direct patient services and an in-house channel for product trials and brand building. PuraPharm also pursues geographic expansion through partnerships, including a collaboration with the University of Graz for European market alignment and a 2025 partnership with Alibaba Cloud to develop a TCM-focused AI platform. Financial data shows persistent net losses across 2021–2025, with reported revenue figures exhibiting apparent unit inconsistencies that limit precision on the absolute revenue base.

Name

PuraPharm

Legal name

PuraPharm International (H.K.) Limited

Website

https://purapharm.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

501–1,000 employees

Short description

PuraPharm is a Hong Kong–headquartered Traditional Chinese Medicine company and the No. 1 CCMG market leader in Hong Kong (70% share), serving TCM practitioners, retail consumers, and clinic patients with standardized granule formulations and branded health products.

Ownership category

akta.pro rank

Product category

Traditional Chinese Medicine (Concentrated Chinese Medicine Granules)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Traditional Chinese medicine
• Chinese medicine granules
• Herbal healthcare products
• Chinese medicine clinics
• Pharmaceutical manufacturing

Headquarters

HQ city

Central

HQ country

Hong Kong SAR China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Concentrated Chinese Medicine Granules (CCMG) Sales: Manufacturing and selling CCMG products for professional use by Chinese Medical Practitioners. PuraPharm is the No. 1 Market Leader in CCMG in Hong Kong with 70% market share and is the only non-PRC company licensed by China NMPA to manufacture and sell CCMG products in China.
2. Healthcare Consumer Products: Research, development, manufacturing and sale of Chinese healthcare products for retail customers including brands such as PuraGold Lingzhi, NONG'S product lines, Haveron hair care, and CardioClear.
3. Nong's Chinese Medicine Clinics: Clinic operations providing patients with high-quality Chinese medical services and safe, reliable, convenient and instant Concentrated Chinese Medicine granules for consumption.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

PuraPharm researches, develops, manufactures, and sells Concentrated Chinese Medicine Granules (CCMG) and a portfolio of Chinese healthcare consumer products (PuraGold Lingzhi, Haveron hair care, CardioClear, Oncozac, Immuzac, Polysac Comb, Arashi Kuni Cordyceps). The company also operates Nong's Chinese Medicine Clinics, providing TCM consultation and treatment with on-site CCMG dispensing, completing a vertically integrated farm-to-clinic solution.

Product overview

PuraPharm operates as a Hong Kong-based Chinese medicine company offering a comprehensive portfolio of concentrated Chinese medicine granules (CCMG) and healthcare products. The core product line is Nong's Concentrated Chinese Medicine Granules, holding 70% market leadership in Hong Kong with over 200 varieties. The product portfolio spans two main categories: Holistic products including PuraGold Lingzhi Extract, NONG'S indigenous herbs and instant drinks, Haveron hair care products, CardioClear cardiac tonic, and various Lingzhi-based formulas; and Therapeutic products including NONG'S CCMG formulas for conditions like flu, cough, sleep disorders, and specialized supplements like Oncozac Yunzhi Capsules and Polysac Comb for immune support. The company also operates Nong's Chinese Medicine Clinics providing integrated clinical services alongside its product offerings.

Differentiator

Problem solved

Functional benefit

Brands

• NONG'S (農本方): Primary brand for concentrated Chinese medicine granules, Chinese medicine clinics, and related healthcare products including flu formulas, cough formulas, and concentrated herbal formulations.
• PuraGold (金靈芝)
• Haveron (烏髮濃)
• Oncozac (安固生)
• Immuzac (益抗適)
• CardioClear (心全一通)
• Polysac Comb
• Arashi Kuni (嵐國)

Products and services

• Nong's Concentrated Chinese Medicine Granules (CCMG) Standardized, modernized concentrated Chinese medicine granules for professional prescription by licensed Chinese Medical Practitioners and use by patients. Covers single herbs, combo formulations, capsules, and topical products.
• PuraGold Lingzhi Extract Premium Lingzhi (Ganoderma) extract product for holistic health maintenance and wellness, sold direct to retail consumers.
• NONG'S Collection of Indigenous Herbs Range of indigenous herbs sourced from native origins with regional characteristics, authenticated using modern scientific identification technologies.
• NONG'S Instant Herbal Drinks Ready-to-drink herbal beverage products for convenient on-the-go consumption.
• NONG'S Concentrated Chinese Medicine Capsules Capsule-formatted concentrated Chinese medicine products offering an easy-to-consume alternative to traditional decoctions.
• Haveron Hair Ultra Strength Formula For Men Male-targeted hair growth supplement formulated with He Shou Wu (Polygonum Multiflorum), Lingzhi, Dang Gui, and Nv Zhen Zi to strengthen hair follicles and promote healthy hair growth.
• Haveron Hair Ultra Strength Formula For Women Female-targeted hair growth supplement designed for women's specific constitution and health conditions.
• Haveron Hair Rejuvenating Shampoo for Men Chinese herbal shampoo for men containing He Shou Wu, Lingzhi, Dang Gui, and Nv Zhen Zi to nourish hair follicles and reduce hair loss.
• Haveron Hair Rejuvenating Shampoo for Women Chinese herbal shampoo for women formulated to address female-pattern hair loss and greying concerns.
• CardioClear Natural Cardiac Tonic Natural cardiac tonic formulated from traditional Chinese herbal ingredients for heart health support.
• PuraPharm Nasal Formula Lingzhi-based formula product marketed for nasal health support.
• PuraPharm Liver Formula Lingzhi-based formula product marketed for liver support.
• Arashi Kuni Cordyceps Mycelium Cordyceps mushroom mycelium product positioned for general health maintenance.
• Polysac Comb Premium Yunzhi (Coriolus Versicolor) extract supplement containing 396mg pharmaceutical-grade extract equivalent to 3.0g dried Yunzhi, marketed to strengthen immune function and improve resistance to serious ailments.
• Oncozac Yunzhi Capsules Yunzhi (Coriolus Versicolor) mushroom capsules marketed for immune support, particularly as a complement to conventional cancer therapy.
• Immuzac Standardized Yuzhi Lingzhi Extract Standardized dual-mushroom extract combining Yunzhi and Lingzhi for enhanced immune support.
• NONG'S Flu Formula — Yin Qiao San Traditional Chinese medicine formula based on Yin Qiao San, used for dispersing wind-heat and clearing away toxic heat associated with flu symptoms.
• NONG'S Cough Formula — Zhi Sou San Traditional Chinese medicine formula based on Zhi Sou San, used to relieve cough and eliminate phlegm.
• NONG'S Dry Throat & Cough Formula — Luo Han Guo Compound Chinese medicine formula featuring Luo Han Guo (Monk Fruit), marketed for clearing heat and moistening the throat.
• NONG'S Sleep Aid Formula — Suan Zao Ren Tang Traditional Chinese medicine formula based on Suan Zao Ren Tang, used to nourish blood, tranquilize the mind, clear heat, and relieve anxiety for sleep support.
• NONG'S Shen Ling Bai Zhu San Traditional formula marketed to relieve discomfort caused by spleen-stomach deficiency (poor digestion, bloating, vomiting, diarrhea, fatigue), replenish qi, remove dampness, and improve spleen-stomach function.
• Nong's Chinese Medicine Clinics Chain of physical Chinese medicine clinics providing patients with high-quality Chinese medical services and instant Concentrated Chinese Medicine granules for in-clinic consumption. Part of PuraPharm's total solution in Chinese medicine products and services.

Quantifiable outcome

• 70% leading market share in Hong Kong CCMG market
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Alibaba CloudcoreTechnology or Integration · 1 January 2025PuraPharm partnered with Alibaba Cloud to develop a Traditional Chinese Medicine AI platform. This collaboration is part of Alibaba Cloud's customer success stories showcasing enterprise innovation powered by full-stack AI and cloud capabilities. The partnership aims to modernize and digitize Traditional Chinese Medicine operations through AI technology.
• National Medical Products Administration (China NMPA)coreStrategic or Co-development PartnerPuraPharm obtained licensing from China NMPA as the only non-PRC company authorized to manufacture and sell Concentrated Chinese Medicine Granules (CCMG) products in China, working with regulatory authorities on quality standards.
• United States Pharmacopeia (USP)coreStrategic or Co-development PartnerPuraPharm collaborated with the United States Pharmacopeia for standardization of CCMG products. The company was the first ever to have CCMG products verified and recognized by USP, with ongoing work on quality standards.
• University of Graz, AustriaminorStrategic or Co-development PartnerPuraPharm is collaborating with University of Graz to develop quality standards for Concentrated Chinese Medicine Granules (CCMG) products suitable for European pharmaceutical retail markets.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Yunnan Baiyao Group: One of China's largest traditional Chinese medicine conglomerates with a broad portfolio of branded TCM and consumer healthcare products. Comparable to PuraPharm as a major branded TCM manufacturer seeking to modernize formulations and expand internationally.
• Beijing Tongrentang: One of China's oldest and most established TCM brands with retail pharmacies, clinics, and consumer products. Comparable to PuraPharm in combining branded TCM manufacturing with a clinic/retail footprint and pursuing international expansion.
• China Traditional Chinese Medicine Holdings (Sinopharm TCM): Subsidiary of Sinopharm focused on concentrated Chinese medicine granules (CCMG), PuraPharm's direct product category. Operates the largest PRC-licensed CCMG manufacturing base, making it the closest direct domestic competitor for China market share.
• CR Sanjiu (China Resources Sanjiu Medical & Pharmaceutical): Large state-backed TCM and OTC pharmaceutical company with branded consumer products including cold/cough remedies, similar to PuraPharm's Nong's line. Competes in both China retail TCM channels and overseas markets.
• Yiling Pharmaceutical: TCM-focused pharmaceutical company known for Lianhua Qingwen, which became globally prominent during COVID-19. Comparable to PuraPharm in pushing TCM formulations toward international regulatory recognition and modern clinical evidence.
• Hutchison China MediTech (Chi-Med): Hong Kong-listed innovative oncology and immunology drug developer with a TCM heritage platform. Comparable to PuraPharm in being a HK-listed, China-rooted healthcare company pursuing international scientific credibility, though focused on novel drug development.

Direct peers

• Tianjiang Pharmaceutical: A major PRC CCMG manufacturer that directly competes with PuraPharm in concentrated Chinese medicine granules. Both companies target practitioner channels and pursue international quality credentials, making them the most direct head-to-head competitors in the segment.
• Eu Yan Sang: Singapore-headquartered TCM company with retail clinics, branded consumer products, and TCM granule offerings across Asia. Closely comparable to PuraPharm in combining TCM retail/clinic operations with branded healthcare products in the Greater China/Southeast Asia region.

Regional players

• Dabur India: One of India's largest Ayurvedic and natural healthcare companies with branded consumer products. Comparable to PuraPharm in modernizing traditional/herbal medicine into branded consumer healthcare SKUs and pursuing international distribution.

Emerging players

• Boiron: French-listed homeopathic medicine manufacturer with international retail distribution of natural/alternative remedies. Comparable to PuraPharm as a regulated alternative-medicine manufacturer pursuing global retail pharmacy placement and quality standardization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/purapharm-corporation-limited

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PuraPharm